Question 1

What is combined oxidative phosphorylation deficiency 48?

Accepted Answer

Combined oxidative phosphorylation deficiency 48 is a multi-system disorder that primarily affects energy production in cells, with notable impact on the brain and muscles. It is caused by changes in the NSUN3 gene, which plays a role in mitochondrial function. The condition typically presents in early life with symptoms such as developmental delay and muscle weakness, among other findings. Precise prevalence estimates are not well established, and the condition is considered extremely rare.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 48?

Accepted Answer

Individuals with combined oxidative phosphorylation deficiency 48 often experience a constellation of neurological, muscular, and metabolic symptoms. Key features include global developmental delay, seizures, and microcephaly, indicating central nervous system involvement. In addition, patients typically exhibit nystagmus, hypotonia, and muscle weakness, along with biochemical abnormalities such as lactic acidosis and increased circulating lactate levels. Brain imaging frequently shows cerebral white matter atrophy and hyperintensity, while abnormalities in the activity of mitochondrial complexes I, III, and IV are consistently seen. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 48?

Accepted Answer

This condition is linked to alterations in the NSUN3 gene, which is important for proper mitochondrial function. The NSUN3 gene is believed to be involved in modifying mitochondrial RNA, a step that is critical for the energy production process. Inheritance is autosomal recessive, meaning that an individual must inherit two altered copies of the gene, one from each parent, in order to manifest the condition. Families with a history of the disorder may benefit from genetic counseling to understand recurrence risks and explore testing options. Associated genes include NSUN3.

Question 4

How is combined oxidative phosphorylation deficiency 48 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 48 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is combined oxidative phosphorylation deficiency 48 diagnosed?

Accepted Answer

The definitive diagnosis of combined oxidative phosphorylation deficiency 48 is established through molecular genetic testing that identifies pathogenic variants in the NSUN3 gene. Clinical evaluation focuses on the characteristic findings such as developmental delay, seizures, muscle weakness, and specific brain imaging abnormalities. While biochemical tests indicating lactic acidosis and reduced mitochondrial complex activities support the diagnosis, genetic confirmation is essential as similar clinical features can occur in other conditions.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 48?

Accepted Answer

Currently, management of combined oxidative phosphorylation deficiency 48 focuses on supportive care and symptom management. Because no treatments have been specifically approved for this condition, therapy is personalized and typically involves a multidisciplinary team of specialists. Supportive strategies may include physical therapy, nutritional support to address failure to thrive, and careful monitoring of metabolic imbalances. Regular surveillance is an essential part of long-term care, helping to identify potential complications before they become serious. Patients and families are encouraged to discuss individualized treatment options with their healthcare team, and genetic counseling is recommended to further inform management and family planning.

Question 7

What are the potential complications of combined oxidative phosphorylation deficiency 48?

Accepted Answer

Individuals with combined oxidative phosphorylation deficiency 48 may face various complications due to their symptoms. These can include challenges with muscle strength, which may affect mobility and daily activities. Additionally, neurological issues like seizures can pose risks and require careful management. Regular monitoring by healthcare providers is essential to identify and address any complications early.

Question 8

How does combined oxidative phosphorylation deficiency 48 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 48 can be challenging for both patients and their families. Daily life may involve therapies like physical therapy to help with muscle weakness and developmental delays. Families often need to adapt their routines to accommodate medical appointments and supportive care. It's important for families to seek support and connect with resources to help manage the condition.

Question 9

What is the prognosis for someone with combined oxidative phosphorylation deficiency 48?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation deficiency 48 can vary widely. Some may experience significant challenges due to neurological and muscular symptoms, while others might have a more stable course with appropriate care. Early intervention and ongoing support from a multidisciplinary team can help improve outcomes. Families are encouraged to discuss expectations and management strategies with their healthcare providers.

Question 10

Are there specific specialists recommended for managing combined oxidative phosphorylation deficiency 48?

Accepted Answer

Managing combined oxidative phosphorylation deficiency 48 typically involves a team of specialists. Families may benefit from working with neurologists for neurological symptoms, genetic counselors for understanding inheritance, and physical therapists for muscle support. A multidisciplinary approach helps address the various aspects of the condition and ensures comprehensive care tailored to the patient's needs.

Research Type	Count	% of Total
Laboratory research	16	59%

Kisho

combined oxidative phosphorylation deficiency 48

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 48

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 48?

What are the symptoms of combined oxidative phosphorylation deficiency 48?

What causes combined oxidative phosphorylation deficiency 48?

How is combined oxidative phosphorylation deficiency 48 inherited?

How is combined oxidative phosphorylation deficiency 48 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 48?

What are the potential complications of combined oxidative phosphorylation deficiency 48?

How does combined oxidative phosphorylation deficiency 48 affect daily life for patients and families?

What is the prognosis for someone with combined oxidative phosphorylation deficiency 48?

Are there specific specialists recommended for managing combined oxidative phosphorylation deficiency 48?

Explore clinical features

Recent Publications